Read Time:12 Second
An Eli Lilly & Co. Alzheimer’s drug won Food and Drug Administration approval Tuesday, capping the medication’s bumpy ride through the U.S. regulatory process and adding a second new treatment option for patients in earlier stages of the disease.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
